210
Participants
Start Date
March 11, 2019
Primary Completion Date
July 8, 2020
Study Completion Date
July 8, 2020
Insulin Aspart SAR341402
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Insulin Aspart
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Insulin glargine U100
Pharmaceutical form: Solution for injection Route of administration: Subcutaneous
Investigational Site Number 8400007, New York
Investigational Site Number 8400023, Baltimore
Investigational Site Number 8400035, Rocky Mount
Investigational Site Number 8400006, Morehead City
Investigational Site Number 8400009, Roswell
Investigational Site Number 8400012, Atlanta
Investigational Site Number 8400005, Columbus
Investigational Site Number 8400030, Miami
Investigational Site Number 8400038, Doral
Investigational Site Number 8400032, New Port Richey
Investigational Site Number 8400033, Palm Harbor
Investigational Site Number 8400026, Ocoee
Investigational Site Number 8400034, Jefferson City
Investigational Site Number 8400018, Lexington
Investigational Site Number 8400004, Flint
Investigational Site Number 8400028, Des Moines
Investigational Site Number 8400019, Crystal Lake
Investigational Site Number 8400031, Washington
Investigational Site Number 8400021, Kansas City
Investigational Site Number 8400036, Omaha
Investigational Site Number 8400016, Mesquite
Investigational Site Number 8400040, Dallas
Investigational Site Number 8400041, Waco
Investigational Site Number 8400027, Houston
Investigational Site Number 8400042, El Paso
Investigational Site Number 8400010, Aurora
Investigational Site Number 8400017, Las Vegas
Investigational Site Number 8400001, Temecula
Investigational Site Number 8400015, Ventura
Investigational Site Number 8400014, Concord
Investigational Site Number 8400029, Waterbury
Investigational Site Number 8400003, Rockville
Investigational Site Number 8400013, Waltham
Lead Sponsor
Sanofi
INDUSTRY